• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

    4/23/25 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email

    SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

    Details on the abstracts are as follows:

    ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

    Abstract #: 861

    Title: Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection

    Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong

    Date/Time: May 8, 2025 at 4:15pm – 5:00pm CET; May 8, 2025 at 8:30am – 5:00pm CET

    Session: Poster Tour; Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

    Abstract #: 856

    Title: The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection

    Presenter: Professor Jinlin Hou, MD, Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

    Date/Time: May 8, 2025 at 8:30am – 5:00pm CET

    Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

    Abstract #: 1924

    Title: Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184

    Presenter: Andreas Jekle, PhD

    Date/Time: May 8, 2025 at 8:30am – 5:00pm CET

    Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

    ALG-055009: Potential best-in-class small molecule THR-β for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Abstract #: 302

    Title: ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD

    Presenter: Stanley Wang, MD, PhD

    Date/Time: May 8, 2025 at 9:45am – 10:30am CET; May 10, 2025 at 8:30am – 4:00pm CET

    Sessions: Poster tour; Poster - MASLD: Therapy

    Abstract #: 2185

    Title: ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study

    Presenter: Megan Fitzgerald, PhD

    Date/Time: May 10, 2025 at 8:30am – 4:00pm CET

    Session: Poster - MASLD: Therapy

    Abstract #: 2152

    Title: Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints

    Presenter: Kha Le, PhD

    Date/Time: May 10, 2025 at 8:30am – 4:00pm CET

    Session: Poster - MASLD: Therapy

    Abstract #: 2001

    Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice

    Presenter: Xuan Luong, PhD

    Date/Time: May 9, 2025 at 8:30am – 5:00pm CET

    Session: Poster - MASLD: Experimental and pathophysiology

    Preclinical

    Abstract #: 2105

    Title: Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates

    Presenter: Jin Hong, PhD

    Date/Time: May 9, 2025 at 8:30am – 5:00pm CET

    Session: Poster - Viral Hepatitis: Experimental and pathophysiology

    About Aligos

    Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

    For more information, please visit www.aligos.com or follow us on LinkedIn or X.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Investor Contact

    Aligos Therapeutics, Inc.

    Jordyn Tarazi

    Vice President, Investor Relations & Corporate Communications

    +1 (650) 910-0427

    [email protected]

    Media Contact

    Inizio Evoke

    Jake Robison

    Vice President

    [email protected]



    Primary Logo

    Get the next $ALGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    1/7/2022$30.00 → $12.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ALGS
    SEC Filings

    See more
    • Aligos Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update

      8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

      6/26/25 4:09:54 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Aligos Therapeutics Inc.

      SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)

      5/15/25 4:20:55 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

      SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      5/15/25 1:53:53 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nuechterlein Carole

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      6/26/25 4:31:16 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Scopa James Paul

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      6/26/25 4:30:56 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hirth Peter

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      6/26/25 4:30:36 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

      SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."

      6/18/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company's stock (the "Inducement Grant") to newly hired employees on June 10, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducement

      6/13/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET. A live webcast of the presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos' website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is

      5/29/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00

      8/19/24 6:51:07 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously

      1/6/23 9:05:04 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously

      1/6/23 9:03:03 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:57:50 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:19:11 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 5:03:16 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care